MHRA's monthly licence list is a cheap supply-chain check as Danish shortages mount

What happened

On 10 November 2026 the MHRA replaced October's file with a November 2026 CSV listing sites that have been granted manufacturing or wholesale dealer licences. The regulator positions it as a monthly resource for checking supply-chain partners. The record does not say how many sites are on the list, who they are, or whether anything in it is unusual, so this piece does not comment on its contents.

The format matters. Because the new file replaces the old one rather than sitting alongside it, anyone who wants a record of earlier months has to save their own copies. That is an operational detail for compliance and supply teams, not a regulatory change.

Why a licence list belongs on a market access desk

Market access teams usually watch reimbursement decisions, tariffs and tender outcomes. Supply continuity is increasingly part of the same conversation. A product that wins a listing but cannot be reliably supplied creates contractual, reputational and pricing risk.

A list of newly licensed manufacturers and wholesalers helps with partner due diligence. It lets teams confirm that a new contract manufacturer, importer or distributor appears among recently licensed sites, and it shows who is entering the UK supply chain. It does not replace a quality audit, and the record gives no indication that the list says anything about inspection outcomes or compliance.

Context: the Danish shortage notices

The Danish Medicines Agency (DKMA) published several supply updates on 13 November that show how manufacturing problems turn into access problems. Each is a Danish market notice, and none relates to the UK list.

Voltabak: DKMA says quality problems are disrupting supply of Laboratoires Thea's diclofenac eye drops. The shortage is expected to run to mid-May 2027. Foreign packs are allowed under section 29(2) of the Danish Medicines Act.

Vivelle Dot 37.5: production problems at Sandoz A/S are disrupting the 37.5 micrograms/24 hours patches. DKMA expects the shortage to last until the end of December, with foreign packs allowed as a stopgap.

Estradiol 25 microgram patches: DKMA has revised the expected period during which a foreign depot patch can be supplied under section 29(2).

Methergin 0.2 mg/ml injection: Essential Pharma Limited has permanently stopped marketing the solution for injection in Denmark from early November 2026, citing production problems.

Taken together, these cases show that manufacturing and quality problems feed straight into availability. Two of the four involve estradiol patches, and the Methergin case is a permanent withdrawal rather than a temporary gap. The records do not say whether the problems are connected, and nothing here suggests the same applies in the UK.

The quality-oversight backdrop

Two Dutch records show the other side of supply assurance. The IGJ has published a manufacturer field safety notice after reports of soft connectors detaching from Intersurgical's sterile and non-sterile breathing systems with Smoothbore tube. It has also released a supervisory report on its July 2026 inspection of Maddox Pharma Swiss BV in Leiden. The available description states no findings or deficiency severity, so no conclusion about that company should be drawn.

The point for market access teams is the range of signals. A licence list says who is authorised, an inspection report may say how a site performed, and a safety notice or shortage notice says what has gone wrong. Each answers a different question, and none can stand in for the others.

Who is affected and what to watch

UK-facing supply, procurement and market access teams that contract with new manufacturers or wholesalers are the most directly affected. So are companies that depend on a single-site supply for products with thin therapeutic alternatives.

For contrast, this week's reimbursement news was in the US. Lucid Diagnostics says Medicare is paying EsoGuard claims at $1,938.01 per test, with coverage granted case by case while a wider MolDX reconsideration remains pending. That is a payer-side story, but it makes the same point: access depends on both the payment decision and the operational ability to deliver.

Open questions remain. The MHRA record does not say whether the list will carry additional fields or how far back it is retained. It is also not yet known whether the Danish shortages will prompt similar pressure on other markets. Teams should watch DKMA's revised dates, particularly the mid-May 2027 horizon for Voltabak.